Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (2.499.991 €): Dencatistat, ein erstklassiger, tumorunabhängiger, oral verfügbarer CTPS1-Inhibitor zur Behandlung gynäkologischer Tumoren Hor 01.06.2026 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Dencatistat, ein erstklassiger, tumorunabhängiger, oral verfügbarer CTPS1-Inhibitor zur Behandlung gynäkologischer Tumoren
Step Pharma is developing dencatistat (STP938), a first-in-class CTPS1 inhibitor that selectively targets CTPS2-null cancers, where tumour cells rely exclusively on CTPS1 for DNA synthesis. This represents a novel tumour-agnostic precision medicine approach that spares healthy tissue, reduces toxicity, and is suitable for oral administration. The current project focuses on advancing dencatistat in gynaecologic cancers, particularly platinum-resistant/refractory ovarian and endometrial tumours, which remain underserved despite high incidence and poor prognosis. The proposal will deliver a Phase 1b clinical trial in 10 biomarker-selected endometrial cancer patients to establish safety and early efficacy, using a validated CTPS2-loss assay. This trial follows a Phase 1a dose-escalation study already underway in ovarian cancer. If successful, a Phase 2 study will be launched with two cohorts (40 biomarker-positive, 40 biomarker-negative) to validate the predictive power of CTPS2-loss and support broader solid tumour expansion. This biomarker-guided strategy will help identify patients most likely to benefit, ensuring cost-efficient clinical development and better outcomes. The EIC grant (€2.5M) will fund critical Phase 1b activities, including patient recruitment, biomarker screening, and regulatory preparation. The requested equity (€10M) will enable Phase 2 execution across ovarian and endometrial cancers. While €37.7M in Series C1 funding has been secured for the ovarian trials, EIC support is essential to unlock the remaining €25M (Series C2) to include the endometrial trial and avoid critical delays in development. This project will lay the foundation for a European-led gynaecologic oncology franchise, with broader application across CTPS2-null solid tumours.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Step Pharma | 2.499.991 € |
Quelle: https://cordis.europa.eu/project/id/101297026
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Step Pharma SAS, Paris, Frankreich.
